Table 5.
Prevalence and concordance between clinician-collected anorectal swabs and serology to detect type-specific HPV among men who did not report receiving any doses of the HPV vaccine (n = 53).
| Type-Specific HPV | DNA Anorectal Swabs n, % |
Serology n, % |
% Agreement a | Kappa (95% CI) | ||
|---|---|---|---|---|---|---|
| 6 | 7 | 13.2% | 21 | 39.6% | 62.3% | 0.11 (−0.11 to 0.33) |
| 11 | 3 | 5.7% | 12 | 22.6% | 79.3% | 0.19 (−0.09 to 0.48) |
| 16 | 7 | 13.2% | 9 | 17.0% | 77.4% | 0.12 (−0.19 to 0.43) |
| 18 | 5 | 9.4% | 7 | 13.2% | 77.4% | −0.12 (−0.24 to 0.01) |
| 31 | 2 | 3.8% | 6 | 11.3% | 84.9% | −0.06 (−0.14 to 0.02) |
| 33 | 0 | 0.0% | 0 | 0.0% | 100.0% | - |
| 35 | - | - | 11 | 20.8% | - | - |
| 45 | 3 | 5.7% | 9 | 17.0% | 81.1% | 0.09 (−0.29 to 0.38) |
| 52 | 0 | 0.0% | 6 | 11.3% | 88.7% | - |
| 58 | 2 | 3.8% | 5 | 9.4% | 86.8% | −0.06 (−0.14 to 0.02) |
a Percent agreement: Sum of results positive for both swabs/serology and negative for both swabs/serology out of all test results in unvaccinated MSM.